Back to Journals » Clinical, Cosmetic and Investigational Dermatology » Volume 3

Update on the use of alitretinoin in treating chronic hand eczema

Authors Pedram Ghasri, Scheinfeld N

Published 19 April 2010 Volume 2010:3 Pages 59—65

DOI https://doi.org/10.2147/CCID.S6495

Review by Single anonymous peer review

Peer reviewer comments 4



Pedram Ghasri1, Noah Scheinfeld2

1University of California, Irvine School of Medicine, Irvine, CA, USA; 2Department of Dermatology, Columbia University, School of Medicine, New York, USA

Abstract: Chronic hand eczema is a debilitating dermatological condition with significant economic, social, and functional impacts. To date, conventional treatments such as topical corticosteroids, phototherapy, and systemic immunosuppressants have yielded disappointing results, owing to either a lack of efficacy or significant adverse events. Oral alitretinoin (9-cis-retinoic acid) is a unique panagonist retinoid with immunomodulatory and anti-inflammatory activity that has emerged as a novel treatment for chronic hand eczema. Several large-scale clinical studies have demonstrated oral alitretinoin’s high efficacy rate of 28% to 89%, its safe tolerability profile, and its positive impact on quality of life, validating it as a therapeutic option for patients with severe chronic hand eczema refractory to standard treatment.

Keywords: hand eczema, alitretinoin, 9-cisretinoic acid

Creative Commons License © 2010 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.